Alopecia areata is not androgenetic hair loss. The distinction matters — because the treatment is completely different.
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
0:00
|
6:53
From Root to Ritual by Laritelle Organic.
This series has covered androgenetic alopecia in depth — DHT, estrogen, cortisol, ferritin, thyroid, microbiome, PIILIF, collagen, Gas6, HIF-1α, the pharmaceutical pipeline. Every mechanism we have discussed assumes a specific biological framework: hair loss driven by hormonal susceptibility, progressive follicle miniaturisation, and the multi-driver cascade that botanical and pharmaceutical treat...
Read the full article: https://laritelleorganic.com/blogs/news/alopecia-areata-is-not-androgenetic-hair-loss-the-distinction-matters-because-the-treatment-is-completely-different
SPEAKER_00
This series has covered androgenetic alopecia in depth, DHT, estrogen, cortisol, ferritin, thyroid, microbiome, PLIF, collagen, gas 6, HIF-1A, the pharmaceutical pipeline. Every mechanism we have discussed assumes a specific biological framework, hair loss driven by hormonal susceptibility, progressive follicle miniaturization, and the multi-driver cascade that botanical and pharmaceutical treatments can address through complementary pathways. That framework applies to alga, it does not apply to alopecia ariata. Alopecia ariata is an autoimmune condition. The immune system identifies the hair follicle as a target and attacks it. The mechanism is not hormonal. The triggers include genetic predisposition and immune dysregulation. The presentation is different, the diagnosis is different, and the treatment is completely different. Understanding whether your hair loss is AGA, AA, or both simultaneously, determines whether everything covered in this series is relevant to your situation, or whether a different clinical path applies entirely. What AA actually is, the autoimmune mechanism, and why it is not what most people assume. Alopecia aureata occurs when T lymphocytes, the immune cells that normally protect against pathogens, breach the immune privilege of the hair follicle and attack the follicle bulb directly. The hair follicle is normally an immune-privileged site. It suppresses local immune activity to protect itself from immune attack during the hair growth cycle. In AA, that privilege collapses, the immune system treats the follicle as foreign tissue and destroys its ability to produce hair. The follicle itself is not damaged beyond recovery in most cases. The follicle is intact, the bulge stem cells are present, the dermal papilla persists. The hair stops growing because the immune attack disrupts the signaling environment the follicle needs to function. Not because the follicle has been permanently destroyed. This is why treatment that restores immune privilege or suppresses the T cell attack can produce dramatic hair regrowth, even in cases of complete scalp loss. How to tell AA from AGA visually. Pattern AGA produces diffuse thinning or defined receding patterns, frontal crown. AA typically produces patchy, sharply defined circular or oval areas of complete hair loss, often described as coin-shaped. The boundary between affected and unaffected areas is usually clear. Eyebrows and eyelashes. AGA does not affect eyebrows, except the outer third in thyroid involvement. AA can affect eyebrows, eyelashes, beard, and body hair. In severe cases, alopecia totalis, alopecia universalis, producing complete hair loss across the entire body. Exclamation mark hairs, a hallmark dermoscopy finding in AA. Short, broken hairs that are narrower at the base than the tip, resembling exclamation marks. These are found at the margins of the patch and are diagnostic. Nail changes. Pitting, ridging, or rough texture in the nails occurs in approximately 1066% of AA patients, a systemic immune involvement not seen in AGA. 2% global lifetime prevalence, approximately 160 million people worldwide, making AA the second most common form of hair loss after AGA 91%. Of baricitinib, 4 mg patients maintained salt, were 20 at 104 weeks, 2 years. With hair regrowth continuing to improve beyond the first year of therapy, 3 FDA-approved JAC inhibitors for AA, baricitinib, adults, rittle citinib, 12 plus, deruxolitinib, requires genetic testing before use, the JAC inhibitor revolution, what the new treatments do, and what they require. The treatment paradigm for severe alopecia ariata has fundamentally shifted. Three FDA-approved JAC inhibitors now offer 23-40% response rates, far exceeding historical steroid outcomes. Jack inhibitors work by targeting and inhibiting JAC enzymes, which play a significant and diverse role in the immune system. Specifically, they block the JACSTAT signaling pathway through which the cytokines driving follicle immune attack are produced. Baricitonib, alumni, FDA, approved 2022, adults 18 plus. The first systemic treatment approved specifically for severe AA. Long-term data confirms sustained efficacy. Nearly 91% of patients receiving baricitinib 4 mg maintained salt, DIRU20 after 104 weeks, with 81.4% achieving salt, Luncha 10, demonstrating that clinical benefits extend well beyond the first year. Patients who did not achieve the primary endpoint at week 52 but remained on treatment continued to show significant improvement. The caveat: Burcitinib requires continuous use. The JAC stat pathway resumes when the drug is stopped, and hair loss typically returns. Using JAK inhibitors over the long term can also change how the medication is distributed, especially for women trying to get pregnant who cannot take JAK inhibitors at that time. Ritlacitinib, Litfulo, FDA, approved 2023, age 12. The first treatment approved for adolescents with AA, a significant development given that AA frequently presents in childhood and adolescence. Ritlocitinib's mechanism includes additional effects on tech kinases, affecting NK cell and cytotoxic T cell activity beyond the primary JAC inhibition. For patients who initially fail to respond to ritlocitinib, switching to brapositoni provided additional benefit in approximately 25% of cases. The most recently approved JAC inhibitor for AA, unique in requiring genetic testing before use, which reflects the increasing precision of pharmacogenomic prescribing in dermatology. Genetic variants affect how individuals metabolize the drug, making pretreatment testing clinically important for efficacy and safety optimization. AGA versus AA, the clinical comparison. What distinguishes them and what to do when both are present. Feature androgenetic alopecia, AGA, alopecia ariata, AA, mechanism, hormonal, DHT receptor sensitivity, follicle miniaturization, autoimmune, T cell attack.